TBPH - Theravance Biopharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TBPH is currently covered by 3 analysts with an average price target of $27.43. This is a potential upside of $8.03 (41.39%) from yesterday's end of day stock price of $19.4.

Theravance Biopharma's activity chart (see below) currently has 101 price targets and 75 ratings on display. The stock rating distribution of TBPH is 85.71% BUY and 14.29% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65.77% with an average time for these price targets to be met of 442.5 days.

Highest price target for TBPH is $40, Lowest price target is $12, average price target is $24.

Most recent stock forecast was given by JULIAN HARRISON from BTIG on 03-Feb-2026. First documented stock forecast 03-Feb-2015.

Currently out of the existing stock ratings of TBPH, 6 are a BUY (85.71%), 1 are a HOLD (14.29%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 12-Apr-2024

$40

$19.52 (95.31%)

$40

8 days ago
(03-Feb-2026)

0/5 (0%)

$20.01 (100.10%)

Buy Since 29-Oct-2019

$20

$-0.48 (-2.34%)

$15

3 months ago
(11-Nov-2025)

14/16 (87.5%)

$1.5 (8.11%)

537

Hold Since 24-Aug-2021

$12

$-8.48 (-41.41%)

$9

11 months 15 days ago
(27-Feb-2025)

6/7 (85.71%)

$2.73 (29.45%)

337

Hold Since 06-Aug-2024

$10

$-10.48 (-51.17%)

$14

1 years 6 months 5 days ago
(06-Aug-2024)

3/3 (100%)

$2.17 (27.71%)

776

Sell Since 16-Sep-2021

$10

$-10.48 (-51.17%)

$10

3 years 6 months 17 days ago
(25-Jul-2022)

3/8 (37.5%)

$0.76 (8.23%)

538

Show more analysts

Please expand the browser size to see the chart

What is TBPH (Theravance Biopharma) average time for price targets to be met?

On average it took 442.5 days on average for the stock forecasts to be realized with a an average price target met ratio 65.77

Which analyst has the current highest performing score on TBPH (Theravance Biopharma) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on TBPH (Theravance Biopharma)?

Josh Schimmer works at CANTOR FITZGERALD and has 3 price targets and 2 ratings on TBPH

Which analyst is the currently most bullish on TBPH (Theravance Biopharma)?

Louise Chen with highest potential upside - $34.52

Which analyst is the currently most reserved on TBPH (Theravance Biopharma)?

Brian Skorney with lowest potential downside - -$13.48

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?